Global Myocardial Infarction Market Report by Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics), Distribution Channels (Hospitals, Hospital Pharmacies, Drug Stores, Online Drug Stores), Regions and Company Analysis 2024-2032
Global Myocardial Infarction Market Analysis
Global Myocardial Infarction Market value is foreseen to be around US$ 3.43 Billion by 2032. The CAGR for the market from 2024 to 2032 is 6.06%. Renub Research states that it amounted to US$ 2.02 Billion in 2023.
A myocardial infarction or heart attack is a risky situation that occurs because an individual does not have sufficient blood flow to some of the heart muscle. This lack of blood flow can arise due to many factors but is commonly associated with a blockage in one or more heart arteries. The affected heart muscle will start to die without blood flow. If the affected individual does not get blood flow back quickly, a myocardial infarction can cause permanent heart harm or death. A heart attack is an existence-threatening emergency. Time is crucial in treating a myocardial infarction. A delay of even a few minutes can bring about everlasting heart damage or demise.
Global Myocardial Infarction Market Growth Opportunities
• Growing cases of Cardiovascular Disorders
Cardiovascular diseases (CVDs) impact the heart and blood arteries. One or more of these disorders may affect a heart or blood vessel component. A person may show no symptoms at all or show some. Major risk factors for heart disease and stroke include high blood pressure, high cholesterol, diabetes, smoking, secondhand smoke exposure, obesity, ineffective weight loss strategies, and an inactive lifestyle.
 In 2021- The World Heart Federation said that more than 50% of a billion people globally continue to be influenced by cardiovascular conditions, which accounted for 20.5 million demises. This is nearly a 3rd of all deaths worldwide and an increase in the envisioned 121 million CVD deaths.
So, the growing instances of cardiovascular illnesses are adding to the boom in the global myocardial infarction market.
• Recent Technological Developments
Controlling myocardial infarction is a pivotal project and a vital juncture in the healthcare panorama in which advancements are reshaping patient care trajectory. The last decade has witnessed a profound transformation, with a burgeoning emphasis on precision medication and innovative interventions. Advanced imaging techniques, including cardiac magnetic resonance imaging (MRI) and computed tomography (CT) angiography, provide a non-invasive window into the myocardium's structure and characteristics. These innovations propel the growth of the industry. The increase in clinical trials and product approvals also drives the global myocardial infarction market.
 In June 2023 - The FDA authorized Lodoco (colchicine) to reduce the threat of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in grownup patients. Developed by Agepha Pharma, Lodoco is the first drug authorized to aim inflammation, an underlying reason for atherosclerotic cardiovascular ailment.
• Increase in Public Campaigns and Endeavours
There has been fantastic growth in public campaigns and initiatives worldwide to increase attention to cardiovascular sicknesses. This is expected to speed up the global myocardial infarction market's growth.
 The 2023 Global Heart Hub Heart Failure Awareness Month Campaign aims to teach the public about Heart Failure. They seek to elevate attention to heart failure's signs, symptoms, and dangerous elements and the significance of early detection and effective management. Their marketing campaign for the year focuses on bringing interest to heart failure through the slogan #HighlightHeartFailure and save lives.
 In August 2023 - the NHS established a lifesaving campaign to inspire people to call 999 while they may be having premature signs and symptoms of a heart attack, as entries for heart attack go back to pre-pandemic levels.
Asia-Pacific Myocardial Infarction Market
Europe might register a substantial share in the global myocardial infarction market. This is due to the significant prevalence of heart disorders in the region.
 The Lancet states in one of its articles that cardiovascular diseases are the leading reason for mortality worldwide, with an alarming 45% of all deaths in Europe attributed to them.
To successfully address the load of cardiovascular disease in Europe, comprehensive actions must be taken at national and regional levels.
 WHO/Europe’s Signature Initiative is a new, collaborative, incredibly targeted, pragmatic version for engaging nations with a high CVD burden to co-define and aid tailor-made tactics for a comprehensive and included technique to restore cardiovascular health.
Europe is further expected to witness a significant increase in the global myocardial infarction market. This is due to product approvals by European regulatory authorities for the remedy of heart sicknesses,
 In 2022 - The European Commission (EC) granted advertising authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic persistent heart failure, Boehringer Ingelheim and Eli Lilly and Company have introduced. The landmark approval makes Jardiance® the primary and handiest accredited treatment for all adults with symptomatic continual heart failure, which includes sufferers across the full spectrum of LVEF, including both heart failure with decreased and preserved ejection fraction.
Global Myocardial Infarction Company News
The major enterprises in the global myocardial infarction industry are Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Merck, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, Boehringer Ingelheim, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, and Mesoblast.
• In April 2024 - Johnson & Johnson will showcase clinical and real-world evidence from its cardiovascular portfolio at the American College of Cardiology's 73rd Annual Scientific Session & Expo. The presentation will include eleven abstracts, including five oral presentations, featuring the therapeutic benefits of breakthrough medicines such as XARELTO® (rivaroxaban) and interventional technologies such as those from Abiomed® and Biosense Webster® to treat cardiovascular diseases.
• In March 2024 - the FDA approved the weight loss drug Wegovy by Novo Nordisk to reduce the risk of serious cardiovascular complications in people with obesity and heart disease.
• In August 2023 - Royal Philips, a global leader in health technology, showcased how it integrates AI in cardiac ultrasound and cardiac care to enhance clinical confidence and efficiency.
• In November 2022 - Johnson & Johnson agreed to purchase Abiomed for USD 16.6 Billion. Abiomed will operate as a separate business and strengthen Johnson & Johnson MedTech's position in cardiovascular innovation. The acquisition will improve the standard of care for heart failure patients.
• In November 2022 - A study presented at the American Heart Association found that tongxiluo, a traditional Chinese herbal ingredient, can reduce mortality risk after a heart attack by 36%. This substance could be a possible adjuvant therapy for treating STEMI, especially in low-income countries.
Drug Class – Market breakup in 9 viewpoints:
1. Antiplatelet Agents
2. Glycoprotein IIb/IIIa Inhibitors
3. Antithrombotic Agents
4. Beta-adrenergic Blockers
5. Vasodilators
6. Angiotensin-converting Enzyme (ACE) Inhibitors
7. Angiotensin-receptor Blockers
8. Analgesics
9. Thrombolytics
Distribution Channel – Market breakup in 4 viewpoints:
1. Hospitals
2. Hospital Pharmacies
3. Drug Stores
4. Online Drug Stores
Countries – Market breakup of 25 Countries:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis
Company Analysis:
1. Pfizer
2. Sanofi-Aventis/Bristol-Myers Squibb
3. AstraZeneca
4. Merck
5. Daiichi Sankyo
6. Eli Lilly and Company
7. Takeda
8. Novartis
9. Genentech
10. Amgen
11. Regeneron/Sanofi
12. Boehringer Ingelheim
13. Idorsia Pharmaceuticals
14. Faraday Pharmaceuticals
15. CSL Behring
16. Immediate Therapeutics
17. Mitsubishi Chemical Group
18. Kancera
19. Bayer
20. Recardio
21. Mesoblast
Report Details:
| Report Features | Details |
| Base Year | 2023 |
| Historical Period | 2019 - 2023 |
| Forecast Period | 2024 - 2032 |
| Market | US$ Million |
| Segment Covered | Drug Class, Distribution Channel, and Countries |
| Countries Covered | United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, and South Africa |
| Companies Covered | Pfizer, Sanofi-Aventis/Bristol-Myers Squibb, AstraZeneca, Merck, Daiichi Sankyo, Eli Lilly and Company, Takeda, Novartis, Genentech, Amgen, Regeneron/Sanofi, Boehringer Ingelheim, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, and Mesoblast |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Exploring the Disease - Background and Key Insights
5.1 Introduction
5.2 Risk Factors
5.3 Pathophysiology
5.4 Diagnosis
5.5 Biomarkers
5.5.1 Biomarkers Originated from Myocardial Tissues
5.5.2 Biomarkers Induced by MI Incidence
5.5.3 Biomarkers Preexisted Before MI Occurred
5.6 Understanding Prior Myocardial Infarction - Definition and Overview
5.6.1 Recurrent MI
5.6.2 Reinfarction
5.6.3 Peri-procedural MI
5.7 Myocardial Infarction - WHO Criteria and Definition
5.7.1 Understanding MI in Category A: Definition and Diagnostic Standards
5.7.2 Category B definition and diagnostic criteria of MI if the requirements for diagnostic tests in Category A (above) Have Not Been Met
5.7.3 Understanding Probable MI in Category C: Definition and Diagnostic Standards
5.7.4 Fourth Universal Definition of Myocardial Infarction: Overview and Key Concepts
6. Comprehensive Treatment and Management
6.1 Antiplatelet agents
6.2 Anticoagulant agents
7. Practical Guidelines and Recommendations for Myocardial Infarction Care
7.1 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines: 2022
7.2 NICE Guidelines for Acute coronary syndromes: 2020
7.3 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation: 2017
7.4 Evidenced-based Recommendations from the Guidelines
7.5 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
8. Global Myocardial Infarction Market
9. Market Share
9.1 Drug Class
9.2 Distribution Channel
9.3 Country
10. Drug Class
10.1 Antiplatelet Agents
10.2 Glycoprotein IIb/IIIa Inhibitors
10.3 Antithrombotic Agents
10.4 Beta-adrenergic Blockers
10.5 Vasodilators
10.6 Angiotensin-converting Enzyme (ACE) Inhibitors
10.7 Angiotensin-receptor Blockers
10.8 Analgesics
10.9 Thrombolytics
11. Distribution Channel
11.1 Hospitals
11.2 Hospital Pharmacies
11.3 Drug Stores
11.4 Online Drug Stores
12. Country
12.1 North America
12.1.1 United States
12.1.2 Canada
12.2 Europe
12.2.1 France
12.2.2 Germany
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
12.2.6 Belgium
12.2.7 Netherlands
12.2.8 Turkey
12.3 Asia Pacific
12.3.1 China
12.3.2 Japan
12.3.3 India
12.3.4 South Korea
12.3.5 Thailand
12.3.6 Malaysia
12.3.7 Indonesia
12.3.8 Australia
12.3.9 New Zealand
12.4 Latin America
12.4.1 Brazil
12.4.2 Mexico
12.4.3 Argentina
12.5 Middle East & Africa
12.5.1 Saudi Arabia
12.5.2 UAE
12.5.3 South Africa
13. Porter’s Five Analysis
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Rivalry
13.4 Threat of New Entrants
13.5 Threat of Substitutes
14. SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threat
15. Analysis of Marketed Therapies
15.1 Key Players
15.2 INSPRA (eplerenone): Pfizer
15.2.1 Description of Drug
15.2.2 Regulatory milestones
15.2.3 Safety and efficacy
15.3 PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
15.3.1 Description of Drug
15.3.2 Regulatory milestones
15.3.3 Safety and efficacy
15.4 BRILINTA (ticagrelor): AstraZeneca
15.4.1 Description of Drug
15.4.2 Regulatory milestones
15.4.3 Safety and efficacy
15.5 ZONTIVITY (vorapaxar): Merck
15.5.1 Description of Drug
15.5.2 Regulatory milestones
15.5.3 Safety and efficacy
15.6 EFFIENT/EFIENT (prasugrel): Daiichi Sankyo/Eli Lilly and Company
15.6.1 Description of Drug
15.6.2 Regulatory milestones
15.6.3 Safety and efficacy
15.7 ATACAND (candesartan): AstraZeneca/Takeda
15.7.1 Description of Drug
15.7.2 Regulatory milestones
15.7.3 Safety and efficacy
15.8 DIOVAN (valsartan): Novartis
15.8.1 Description of Drug
15.8.2 Regulatory milestones
15.8.3 Safety and efficacy
15.9 TNKASE (tenecteplase): Genentech
15.9.1 Description of Drug
15.9.2 Regulatory milestones
15.9.3 Safety and efficacy
15.10 REPATHA (evolocumab): Amgen
15.10.1 Description of Drug
15.10.2 Regulatory milestones
15.10.3 Safety and efficacy
15.11 PRALUENT (alirocumab): Regeneron/Sanofi
15.11.1 Description of Drug
15.11.2 Regulatory milestones
15.11.3 Safety and efficacy
16. Analysis of Emerging Therapies
16.1 Key Players
16.2 FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
16.2.1 Description of Drug
16.2.2 Clinical Research & Development
16.2.3 Safety and efficacy
16.3 JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
16.3.1 Description of Drug
16.3.2 Clinical Research & Development
16.3.3 Safety and efficacy
16.4 Pelacarsen (TQJ230): Novartis
16.4.1 Description of Drug
16.4.2 Clinical Research & Development
16.4.3 Safety and efficacy
16.5 Olpasiran: Amgen
16.5.1 Description of Drug
16.5.2 Clinical Research & Development
16.5.3 Safety and efficacy
16.6 Selatogrel: Idorsia Pharmaceuticals
16.6.1 Description of Drug
16.6.2 Clinical Research & Development
16.6.3 Safety and efficacy
16.7 FDY-5301: Faraday Pharmaceuticals
16.7.1 Description of Drug
16.7.2 Clinical Research & Development
16.7.3 Safety and efficacy
16.8 CSL112: CSL Behring
16.8.1 Description of Drug
16.8.2 Clinical Research & Development
16.8.3 Safety and efficacy
16.9 IMT-358: Immediate Therapeutics
16.9.1 Description of Drug
16.9.2 Clinical Research & Development
16.9.3 Safety and efficacy
16.10 CL2020: Mitsubishi Chemical Group
16.10.1 Description of Drug
16.10.2 Clinical Research & Development
16.10.3 Safety and efficacy
16.11 MEDI6570: AstraZeneca
16.11.1 Description of Drug
16.11.2 Clinical Research & Development
16.11.3 Safety and efficacy
16.12 KAND567: Kancera
16.12.1 Description of Drug
16.12.2 Clinical Research & Development
16.12.3 Safety and efficacy
16.13 Asundexian: Bayer
16.13.1 Description of Drug
16.13.2 Clinical Research & Development
16.13.3 Safety and efficacy
16.14 Dutogliptin: Recardio
16.14.1 Description of Drug
16.14.2 Clinical Research & Development
16.14.3 Safety and efficacy
16.15 MPC-25-IC: Mesoblast
16.15.1 Description of Drug
16.15.2 Clinical Research & Development
16.15.3 Safety and efficacy
17. Regulations and Reimbursement
17.1 PRALUENT (alirocumab)
17.2 INSPRA (eplerenone)
17.3 BRILINTA (ticagrelor)
17.4 REPATHA (evolocumab)
17.5 DIOVAN (valsartan)
17.6 ZONTIVITY (vorapaxar)
17.7 TNKase (tenecteplase)
17.8 Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com